Treatment of congestive heart failure - a neuroendocrine disorder

被引：6

作者：

Martin, MWS ^{[1
]}

机构：

[1] Vet Cardioresp Ctr, Kenilworth CV8 1JL, Warwick, England

来源：

JOURNAL OF SMALL ANIMAL PRACTICE | 2003年 / 44卷 / 04期

关键词：

D O I：

10.1111/j.1748-5827.2003.tb00137.x

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

The understanding of heart failure is no longer based on a supply and demand model of pump failure. Rather, heart failure is seen as a complex pathophysiological process with activation of various neuroendocrine systems. The goals of treatment have changed towards modifying these counterproductive neuroendocrine systems and slowing myocardial maladaptation. Angiotensin converting enzyme inhibitors are the only licensed drugs in veterinary practice that have a direct effect on neurohormones in heart failure. The range of drug options in human medicine is greater and some of these drugs are also increasingly being used in veterinary cardiology practice. This review describes the neuroendocrine systems involved in heart failure and discusses the range of drugs available in human and veterinary medicine. In doing so, it concentrates on the evidence available from good quality randomised trials in both the veterinary field and, where relevant, the human medical field.

引用

页码：154 / 160

页数：7

共 43 条

[1] Pathophysiology of pediatric heart failure [J].

Auslender, M .

PROGRESS IN PEDIATRIC CARDIOLOGY, 2000, 11 (03) :175-184

[2]

BENCH (BENazepril in Canine Heart disease) Study Group, 1999, J Vet Cardiol, V1, P7, DOI 10.1016/S1760-2734(06)70025-X

[3] Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats [J].

Bozkurt, B ;

Kribbs, SB ;

Clubb, FJ ;

Michael, LH ;

Didenko, VV ;

Hornsby, PJ ;

Seta, Y ;

Oral, H ;

Spinale, FG ;

Mann, DL .

CIRCULATION, 1998, 97 (14) :1382-1391

[4] Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure [J].

Cleland, JGF ;

Swedberg, K .

LANCET, 1998, 351 (9116) :1657-1658

[5] ATRIAL-NATRIURETIC-FACTOR IN NORMAL SUBJECTS AND HEART-FAILURE PATIENTS - PLASMA-LEVELS AND RENAL, HORMONAL, AND HEMODYNAMIC-RESPONSES TO PEPTIDE INFUSION [J].

CODY, RJ ;

ATLAS, SA ;

LARAGH, JH ;

KUBO, SH ;

COVIT, AB ;

RYMAN, KS ;

SHAKNOVICH, A ;

PONDOLFINO, K ;

CLARK, M ;

CAMARGO, MJF ;

SCARBOROUGH, RM ;

LEWICKI, JA .

JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (05) :1362-1374

[6] A COMPARISON OF ENALAPRIL WITH HYDRALAZINE ISOSORBIDE DINITRATE IN THE TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE [J].

COHN, JN ;

JOHNSON, G ;

ZIESCHE, S ;

COBB, F ;

FRANCIS, G ;

TRISTANI, F ;

SMITH, R ;

DUNKMAN, WB ;

LOEB, H ;

WONG, ML ;

BHAT, G ;

GOLDMAN, S ;

FLETCHER, RD ;

DOHERTY, J ;

HUGHES, CV ;

CARSON, P ;

CINTRON, G ;

SHABETAI, R ;

HAAKENSON, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) :303-310

[7] Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. [J].

Colucci, WS ;

Elkayam, U ;

Horton, DP ;

Abraham, WT ;

Bourge, RC ;

Johnson, AD ;

Wagoner, LE ;

Givertz, MM ;

Liang, CS ;

Neibaur, M ;

Haught, WH .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04) :246-253

[8] SAFETY AND EFFICACY STUDY OF DELAPRIL VERSUS ENALAPRIL IN PATIENTS WITH CONGESTIVE-HEART-FAILURE [J].

DALLAVOLTA, S .

AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (16) :F44-F49

[9] Impaired endothelium-mediated vasodilation in heart failure: Clinical evidence and the potential for therapy [J].

Elkayam, U ;

Khan, S ;

Mehboob, A ;

Ahsan, N .

JOURNAL OF CARDIAC FAILURE, 2002, 8 (01) :15-20

[10]

Ettinger SJ, 1998, J AM VET MED ASSOC, V213, P1573

← 1 2 3 4 5 →